Elan and Biogen Idec’s ongoing safety evaluation of TYSABRI has led to a previously diagnosed case of malignant astrocytoma being reassessed as progressive multifocal leukoencephalopathy (PML).
Shares of Elan and Biogen Idec Shares Rise
Shares of Elan and Biogen Idec went up following the companies’ announcement of their multiple sclerosis drug Tysabri test results.